Smartest Doc
A 12-week, Double-masked, Parallel-group Study of the Safety and Efficacy of Travoprost 0.004% Compared With Pilocarpine 1% in Chinese Patients With Primary Angle-closure and Primary Angle-closure Glaucoma
Journal of Glaucoma, 08/08/2011
Clinical Article
Wu LL et al. – Travoprost 0.004% once daily provides effective intraocular pressure (IOP)–lowering efficacy with significantly greater IOP reduction from baseline when compared with pilocarpine 1% 4 times daily at 4 PM over the 12–week period. Travoprost 0.004% once daily is safe and well tolerated in primary angle–closure (PAC) or primary angle–closure glaucoma (PACG) patients.
